Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(50%)
Terminated
1(17%)

Phase Distribution

Ph early_phase_1
1
17%
Ph phase_3
1
17%
Ph not_applicable
1
17%
Ph phase_2
3
50%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Terminated(2)

Detailed Status

Recruiting2
Not yet recruiting1
Terminated1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
N/A1 (16.7%)

Trials by Status

not_yet_recruiting117%
terminated117%
withdrawn117%
active_not_recruiting117%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

NCT06246357
not_yet_recruitingearly_phase_1

Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)

NCT07007325
terminatedphase_3

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

NCT06125028
active_not_recruitingphase_2

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

NCT04561492
recruitingnot_applicable

PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

NCT06871176
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06246357Phase 2

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Recruiting
NCT07007325Early Phase 1

Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)

Not Yet Recruiting
NCT06125028Phase 3

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Terminated
NCT04561492Phase 2

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

Active Not Recruiting
NCT06871176Not Applicable

PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

Recruiting
NCT05321862Phase 2

Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6